Proviron vs Masteron: complete comparison (DHT-derivatives, opposite profiles)
| Critère | proviron | masteron |
|---|---|---|
| Form | Oral (proviron) | Injectable (masteron) |
| Anabolic effect | Negligible | Moderate (ratio 62:25) |
| Half-life | ~12 h | 2 d (prop) / 5 d (enanthate) |
| Hepatotoxicity | Low (non-17α-alkylated) | Low (injection) |
| Aromatization | No | No |
| Libido effect | Marked (positive) | Moderate (variable) |
| Typical dose | 25-100 mg/d | 400-600 mg/week |
| Main use | Cycle adjunct / SHBG | Cutting / pre-contest |
Quand choisir proviron
Proviron (mesterolone) is a non-17α-alkylated oral DHT-derivative, making it one of the rare orals with low hepatic toxicity. Originally developed to treat male infertility (WHO 1989: improvement in sperm quality in some hypogonadics), it has weak intrinsic anabolic activity at practical doses but acts as a hormonal comfort adjunct during a cycle. Choose it for: (1) increasing available free testosterone in cycle (SHBG displacement effect, like masteron but oral), (2) boosting libido mid-cycle (effect felt from D3-D5), (3) adding a mild functional anti-estrogen effect by receptor competition, (4) improving visual quality in finish (drier skin, moderate vascularity). Typical dose 25-50 mg/d in cycle (often split in 2 intakes), rising to 100 mg/d at end of cut cycle for maximum effect. Favorable tolerance profile (Kicman 2008): no notable hepatic toxicity, no aromatization. Drawbacks: marked androgenic profile (acne and hair loss possible in those predisposed to androgenetic alopecia), modest visual effect compared to injectable masteron, and relatively high cost for its real utility. Not a cycle molecule per se — an adjunct.
Quand choisir masteron
Masteron (drostanolone) is a DHT-derivative injectable oriented toward aesthetic finish (Chowdhury 1976, Saartok 1984). Choose it when you want to add visual hardness, vascularity and a mild anti-estrogenic effect to a cutting cycle. Its distinctive mechanism: marked displacement of testosterone from SHBG (free testo increase), competition at the estrogen receptor (functional anti-E2 effect without aromatase inhibition), and DHT-like activity on the skin (dryness, finish). Modest anabolic profile (ratio 62:25) but superior to proviron: it makes you gain some net lean mass (+2-3 kg over 12 weeks at 500 mg/week). Ideal in the last 8-10 weeks before competition or to finish a cycle. Favorable tolerance profile (Kicman 2008): no aromatization, low hepatotoxicity (injection), moderate suppression. Drawbacks: marked androgenic profile (acne, hair loss), visual effect apparent only if body fat < 12% (masteron polishes, does not cut), and need for frequent propionate injections (3× per week). Typical dose 400-600 mg/week.
Combinaison ?
The proviron + masteron + testosterone combo is a major classic of competitive finish. Typical scheme: testo prop 100 mg EOD + masteron prop 100 mg EOD + proviron 50 mg/d in the last 8-10 weeks before competition. All three molecules are DHT-derivatives or testosterone itself: competitive cut profile without major toxicity. Proviron amplifies masteron's SHBG-displacement effect (maximized free testosterone), brings a practical oral complement between injections, and boosts the libido often weakened in pre-competition by caloric deficit and moderate-dose testosterone. No strong AI necessary (moderate-dose testo + double functional anti-E2 masteron+proviron); anastrozole 0.25 mg 2× per week as precaution remains. Monitoring: E2 at W4, lipids at W6, T total at W0/W6. Virilization monitoring in women (proviron + masteron can virilize at moderate dose). Classic PCT 2 weeks after last injection. Sample contest-prep 10-week timeline: W0 baseline E2 and T total, W2 first E2 measurement (low risk under combo), W4 lipids + ALT/AST + virilization check if female, W6 mid-cycle adjustment, W8 final pre-show optimization, W10 last injection, W12 PCT start, W18 post-PCT. Female user variant: proviron 12.5 mg/d + masteron prop 50 mg EOD + testo prop 25 mg EOD × 6 weeks max with weekly virilization assessment (acne, voice, hirsutism, clitoral changes). Practical synergy consideration: the proviron oral allows fine titration of perceived hardness day-to-day without committing to a new injection schedule. Many competitors front-load proviron in the last 2 weeks pre-show (75-100 mg/d) for maximum visual effect. Sample baseline panel must include CBC, comprehensive metabolic panel, lipids, ALT/AST, T total, free T, SHBG, E2, prolactin, and resting BP averaged over three days. Free testosterone matters here because both proviron and masteron primarily act by displacing testosterone from SHBG, so measuring SHBG and free T (not just total T) is the relevant pharmacological signal.
FAQ
- Is proviron an anabolic steroid?
- Technically yes (it is a DHT-derivative structurally androgenic), but in practice its direct anabolic effect is negligible at recreational doses (25-100 mg/d). The anabolic/androgenic ratio of mesterolone is very unfavorable to muscle (low affinity for muscular vs cutaneous androgen receptor). Its real utility is mechanical: displacement of testosterone from SHBG (free testo increase), anti-estrogen effect by receptor competition, and libido support. Not a molecule for gaining muscle, but a useful adjunct in cycle.
- Can you run a proviron-only cycle?
- Theoretically yes, but without practical interest. Proviron modestly suppresses the HPG axis (less than exogenous testo), produces few anabolic gains, and costs more than an equivalent testosterone dose. Its solo use only makes sense as 'bridge' between cycles in users wanting to maintain libido during post-PCT phase (50 mg/d × 4 weeks) — and even then, clean TRT is preferable if hormonal support need is real and prolonged.
- Proviron to boost libido in cycle?
- Yes, one of its most relevant uses. Libido is often weakened in cycle for several reasons: estradiol too low (under-AI), elevated prolactin (under nandrolone or trenbolone), or simply functional androgen deficit (insufficient free testosterone). Proviron 25-50 mg/d quickly corrects (from D3-D5) by increasing available free testo. It is the practical antidote to moderate 'deca-dick'. If effect does not manifest at 50 mg/d, first check E2 and prolactin.
- How much virilization possible in women?
- Real risk from 25 mg/d in women. Proviron is an androgenic DHT-derivative, so even at low dose it can induce acne, hirsutism, deep voice, clitoral hypertrophy. If female use (rare and inadvisable), ceiling dose 12.5 mg/d × 4 weeks maximum with weekly virilization monitoring and immediate stop at first sign. Anavar remains the preferable oral alternative for women.
- Proviron or masteron to reduce E2?
- Masteron for a more marked functional anti-E2 effect (strong receptor competition, more powerful SHBG displacement). Proviron for a more modest but oral effect, practical as complement. Neither is a true aromatase inhibitor — they do not lower serum estradiol, they reduce its biological effect by competing at the receptor. To lower measured E2, you need anastrozole, exemestane or letrozole. The proviron + AI combination is coherent: AI lowers level, proviron reduces residual effect.
- Do you need PCT after proviron alone?
- Modest but often yes. Proviron weakly suppresses the HPG axis (Kicman 2008), especially at high dose (100 mg/d) or long cycle (> 8 weeks). For a 4-6 week cycle at 50 mg/d, a minimal PCT (nolvadex 20 mg/d × 3-4 weeks) suffices. For longer cycles, follow classic SERM scheme. If proviron cycle is paired with a testosterone cycle, the overall cycle PCT takes over.
- Does proviron really improve fertility?
- Modest and variable effect. WHO 1989 documented improvement of certain sperm parameters (motility, morphology) in some hypogonadics under mesterolone at 75-100 mg/d over 3-6 months. But mesterolone also modestly suppresses LH and therefore endogenous spermatogenesis. Net: limited positive effect, and only in specific subpopulations. For post-cycle fertility or hypogonadism, hCG and clomid remain first lines (Liu 2002, Coviello 2005).
- Proviron + AI combination: useful or redundant?
- Complementary, not redundant. AI (anastrozole, exemestane, letrozole) lowers serum estradiol by inhibiting aromatase. Proviron does not touch level but reduces residual biological effect by estrogen receptor competition. Coherent combination: dose-dependent AI to bring E2 in 80-150 pmol/L window, proviron 25-50 mg/d to attenuate residual E2 effects and boost free testo. Useful in users sensitive to estrogenic retention or gynecomastia.